DOSIS OCTREOTIDE PDF
Sandostatin Injection is available as: sterile 1-mL ampuls in 3 strengths, containing 50, mcg octreotide (as acetate), and sterile 5-mL multi-dose vials in 2. Sep 3, Octreotide Acetate (Sandostatin ®) – Intravenous (IV) Dilution. Octreotide (Sandostatin) is the longer acting synthetic analogue of the naturally In patients with cancer and inoperable bowel obstruction octreotide rapidly.
|Published (Last):||19 June 2010|
|PDF File Size:||12.82 Mb|
|ePub File Size:||4.83 Mb|
|Price:||Free* [*Free Regsitration Required]|
If the treatment is stopped, symptoms may worsen or recur. Cotreotide endocrine tumours Initially 0. Oesophageal varices Since, following bleeding episodes from oesophageal varices, there is an increased risk for the development of insulin-dependent diabetes or for changes in insulin requirement in patients with pre-existing diabetes, an appropriate monitoring of blood glucose levels is mandatory.
Local Site Reactions In a week toxicity study in rats, predominantly in males, sarcomas were noted at the s. Continue typing to refine. Sites should be rotated in a systematic manner. Octreotide inhibits secretion of cholecystokinin, resulting in reduced contractility of the gallbladder and an increased risk of sludge and stone formation.
Diarrhoea, abdominal pain, nausea, constipation, flatulence.
The diluted solutions of Octreotide Hospira octreotide acetate in 0. Bradycardia is a common adverse reaction with somatostatin analogues. Octreotide’s effects in the different tumour types are lctreotide follows: Keep the vial in the outer carton in order to protect from light. The following drugs require monitoring and possible dose adjustment when used with Sandostatin LAR Depot: Symptomatic control and reduction of growth hormone GH and IGF-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy.
Contains less than 1 mmol 23 mg sodium per dose, i. Clinical improvement is usually accompanied dosia a reduction in plasma VIP levels, which may fall into the normal reference range. Treatment of TSH-secreting pituitary adenomas The dosage most generally effective is micrograms three times a day by s.
Show table of contents Hide table of contents 1. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: Pain or a sensation of stinging, tingling or burning at the site of s. Posology Acromegaly Initially 0. In cirrhotic patients with bleeding gastro-oesophageal varices, Sandostatin has been well tolerated at continuous i.
Metabolism and nutrition disorders Very common: Late descent of the testes was found for male offsprings of dam treated during pregnancy and lactation. Somatostatin and analogues ATC code: Somatostatin and analogues, ATC code: Treatment of TSH-secreting pituitary adenomas The treatment effects of Sandostatin were prospectively observed in 21 patients and pooled with series of 37 published cases. Hypersensitivity and allergic reactions have been octreotiee during post-marketing experience.
This site is for US health care professionals only. VIPomas Daily dosages of mcg in divided doses are recommended during the initial 2 weeks of therapy range mcg to control symptoms of the disease. Maintenance doses have to be adjusted individually.
In rare instances, gastrointestinal side effects may resemble acute intestinal obstruction, with progressive abdominal distension, severe epigastric pain, abdominal tenderness and guarding. It is therefore recommended to monitor glucose tolerance and antidiabetic treatment.
Dosing & Administration
Blood glucose levels should be monitored when Sandostatin LAR Depot treatment is initiated or when the dose is octdeotide. Clinical improvement is usually accompanied by a reduction in plasma VIP levels, which may fall into the normal reference range. Use in patients with impaired renal function Impaired renal function did not affect the total exposure AUC to octreotide administered as s. For Patients not currently receiving octreotide acetate Begin therapy with Sandostatin Immediate-release Injection.
Sandostatin® LAR Depot Dosing & Administration | HCP
Dksis is a very common event during Sandostatin octreotidd and may be associated with cholecystitis and biliary duct dilatation see section 4.
Tabulated list of adverse reactions The following adverse drug reactions, listed in Table 1, have been accumulated from clinical studies with octreotide: In some patients, computed tomography scanning suggests a slowing or arrest of progression of the tumour, or even tumour shrinkage, particularly of hepatic metastases. Short-acting Sandostatin Immediate-release Injection should be continued for at least 2 weeks following initial injection of Sandostatin LAR Depot 20 mg.
Octreotife elimination capacity may be reduced in patients with liver cirrhosis, but not in patients with fatty liver disease.
Female patients of childbearing potential should be advised to use adequate contraception if necessary during treatment with octreotide see section 4. Octreotide produces improvement of diarrhoea, and hence weight gain, in those patients affected. Ultrasonic examination of the gallbladder before, and at about 6- to month intervals during Sandostatin therapy is therefore recommended.
Concomitant administration of octreotide and bromocriptine increases the bioavailability of bromocriptine. Thyroid function should be octreoitde in patients receiving prolonged treatment with octreotide.